학술논문
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study’s analysis of heavily pretreated patients
Document Type
article
Author
Sebastiano Buti; Alessandro Olivari; Cristina Masini; Davide Bimbatti; Donata Sartori; Paola Ermacora; Carlo Cattrini; Maria Giuseppa Vitale; Ernesto Rossi; Claudia Mucciarini; Mimma Rizzo; Michele Sisani; Matteo Santoni; Giandomenico Roviello; Veronica Mollica; Vincenza Conteduca; Francesco Grillone; Marika Cinausero; Giuseppe Prati; Francesco Atzori; Marco Stellato; Francesco Massari; Melissa Bersanelli
Source
Therapeutic Advances in Urology, Vol 16 (2024)
Subject
Language
English
ISSN
1756-2880
17562872
17562872
Abstract
Background: The treatment of heavily pretreated patients with metastatic renal cell carcinoma (mRCC) represents an unmet medical need and is still challenging. Objectives: The primary objective was to assess the effectiveness of the lenvatinib plus everolimus combination and the secondary objective was the toxicity profile of this combination. Design: We conducted a longitudinal retrospective study examining mRCC patients pre-treated with one or more lines of therapy among different cancer centers in Italy. Methods: The study included patients who received the combination of lenvatinib plus everolimus as either a second-line treatment or beyond. We assessed progression-free survival (PFS), time to treatment failure (TTF), overall survival (OS), response rate (RR), and toxicity profile. In addition, we explored the potential relationship between treatment effectiveness and clinical and laboratory parameters. Results: In all, 33 patients were assessed, the median age was 60 years, 57% had an Eastern Cooperative Oncology Group performance status of 1–2 and. 63% received ⩾ 3 prior lines of therapy. 62% were ‘intermediate risk’ according to the International Metastatic Renal Cell Carcinoma Database Consortium and 30% were ‘poor risk’. The RR was 42% (no complete response), 18% stable disease. Median OS was 11.2 months (95% CI 6.8–19.9), median PFS was 6.7 months (95% CI 0.6–30.8), and median TTF was 6.7 months (95% CI 4.8–16.6). A shorter OS was significantly associated with lymph node metastases ( p = 0.043, 95% CI), neutrophils/ lymphocytes ratio (NLR) ⩾ 3 ( p = 0.007), hemoglobin/red cell distribution width ratio cutoff value